R. Siegel, D. Naishadham, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.63, pp.11-30, 2013.

M. Ducreux, A. Adenis, and J. P. Pignon, Efficacy and safety of bevacizumab -based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study), Eur J Cancer, vol.49, pp.1236-1281, 2013.

L. C. Ye, T. S. Liu, and L. Ren, Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases, J Clin Oncol, vol.31, pp.1931-1939, 2013.

C. De-divitiis, G. Nasti, M. Montano, R. Fisichella, R. V. Iaffaioli et al., Prognostic and predictive response factors in colorectal cancer patients: between hope and reality, World J Gastroenterol, vol.20, pp.15049-59, 2014.

J. A. Meyerhardt, C. H. Kroenke, and C. M. Prado, Association of weight change after colorectal cancer diagnosis and outcomes in the Kaiser Permanente northern California population, Cancer Epidemiol Biomark Prev, vol.26, pp.30-37, 2017.

L. Martin, L. Birdsell, and N. Macdonald, Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index, J Clin Oncol, vol.31, pp.1539-1586, 2013.

C. Feliciano, E. Kroenke, and C. H. , Association of systemic inflammation and sarcopenia with survival in non-metastatic colorectal cancer: results from the C SCANS study, JAMA Oncol, vol.3, p.172319, 2017.

H. W. Jung, J. W. Kim, and J. Y. Kim, Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy, Support Care Cancer, vol.23, pp.687-94, 2015.

G. Malietzis, A. C. Currie, and T. Athanasiou, Influence of body composition profile on outcomes following colorectal cancer surgery, Br J Surg, vol.103, pp.572-80, 2016.

J. R. Lieffers, M. Mourtzakis, K. D. Hall, L. J. Mccargar, C. M. Prado et al., A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands, Am J Clin Nutr, vol.89, pp.1173-1182, 2009.

T. Endo, C. Momoki, and M. Yamaoka, Validation of skeletal muscle volume as a nutritional assessment in patients with gastric or colorectal cancer before radical surgery, J Clin Med Res, vol.9, pp.844-59, 2017.

S. Chemama, M. A. Bayar, and E. Lanoy, Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer, Ann Surg Oncol, vol.23, pp.3891-3899, 2016.

S. Antoun, I. Borget, and E. Lanoy, Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer, Curr Opin Support Palliat Care, vol.7, pp.383-392, 2013.

B. Sjøblom, J. ?. Benth, and B. H. Grønberg, Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer, Clin Lung Cancer, vol.18, pp.129-165, 2017.

C. M. Prado, Y. L. Maia, M. Ormsbee, M. B. Sawyer, and V. E. Baracos, Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics, Anti Cancer Agents Med Chem, vol.13, pp.1197-203, 2013.

M. Barret, S. Antoun, and C. Dalban, Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer, Nutr Cancer, vol.66, pp.583-592, 2014.

R. Ali, V. E. Baracos, and M. B. Sawyer, Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens, Cancer Med, vol.5, pp.607-623, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01881582

C. Feliciano, E. M. Lee, and V. S. , Muscle mass at the time of diagnosis of non-metastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: the C-SCANS study, Cancer, vol.123, pp.4868-77, 2017.

S. Blauwhoff-buskermolen, K. S. Versteeg, and M. A. De-van-der-schueren, Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer, J Clin Oncol, vol.34, pp.1339-1383, 2016.

G. Malietzis, A. C. Currie, and N. Johns, Skeletal muscle changes after elective colorectal cancer resection: a longitudinal study, Ann Surg Oncol, vol.23, pp.2539-2586, 2016.

C. M. Prado, M. B. Sawyer, and S. Ghosh, Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?, Am J Clin Nutr, vol.98, pp.1012-1021, 2013.

S. Antoun, L. Birdsell, M. B. Sawyer, P. Venner, B. Escudier et al., Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo -controlled study, J Clin Oncol, vol.28, pp.1054-60, 2010.

P. Atlan, M. A. Bayar, and E. Lanoy, Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study, Support Care Cancer, vol.25, pp.3365-73, 2017.

C. M. Prado, J. R. Lieffers, and L. J. Mccargar, Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, Lancet Oncol, vol.9, pp.629-664, 2008.

W. Shen, M. Punyanitya, and Z. Wang, Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image, J Appl Physiol, vol.9, pp.2333-2341, 1985.

M. Mourtzakis, C. M. Prado, J. R. Lieffers, T. Reiman, L. J. Mccargar et al., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Appl Physiol Nutr Metab, vol.33, pp.997-1006, 2008.

B. H. Goodpaster, D. E. Kelley, F. L. Thaete, J. He, and R. Ross, Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content, J Appl Physiol, vol.89, pp.104-114, 1985.

M. Schemper and T. L. Smith, A note on quantifying follow-up in studies of failure time, Control Clin Trials, vol.17, pp.343-349, 1996.

M. A. Bayar, S. Antoun, and E. Lanoy, Statistical approaches for evaluating body composition markers in clinical cancer research, Expert Rev Anticancer Ther, vol.17, pp.311-319, 2017.

S. T. Mcsorley, D. H. Black, P. G. Horgan, and D. C. Mcmillan, The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer, Clin Nutr, vol.37, pp.1279-85, 2018.

J. J. Hopkins, D. Skubleny, D. L. Bigam, V. E. Baracos, D. T. Eurich et al., Barriers to the interpretation of body composition in colorectal Cancer: a review of the methodological inconsistency and complexity of the CT -defined body habitus, Ann Surg Oncol, vol.25, pp.1381-94, 2018.

C. M. Prado, V. E. Baracos, and L. J. Mccargar, Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity, Clin Cancer Res, vol.13, pp.3264-3272, 2007.

N. A. Stephens, R. J. Skipworth, A. J. Macdonald, C. A. Greig, J. A. Ross et al., Intramyocellular lipid droplets increase with progression of cachexia in cancer patients, J Cachexia Sarcopenia Muscle, vol.2, pp.111-118, 2011.

M. J. Lee, Y. Wu, and S. K. Fried, Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications, Mol Asp Med, vol.34, pp.1-11, 2013.

T. Poterucha, B. Burnette, and A. Jatoi, A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab, Med Oncol, vol.29, pp.1005-1014, 2012.

S. A. Kurk, P. Peeters, B. Dorresteijn, P. A. De-jong, J. M. Kuijf et al., Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients, J Cachexia Sarcopenia Muscle, vol.9, pp.909-928, 2018.

L. A. Gilliam, L. F. Ferreira, and J. D. Bruton, Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle, J Appl Physiol, vol.107, pp.1935-1977, 1985.

K. Van-norren, A. Van-helvoort, and J. M. Argilés, Direct effects of doxorubicin on skeletal muscle contribute to fatigue, Br J Cancer, vol.100, pp.311-315, 2009.

P. Hojman, J. Fjelbye, and B. Zerahn, Voluntary exercise prevents cisplatin-induced muscle wasting during chemotherapy in mice, PLoS One, vol.9, p.109030, 2014.

R. Barreto, D. L. Waning, H. Gao, Y. Liu, T. A. Zimmers et al., Chemotherapy -related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs, Oncotarget, vol.7, pp.43442-60, 2016.

A. Van-der-werf, K. Arthey, and M. Hiesmayr, The determinants of reduced dietary intake in hospitalised colorectal cancer patients, Support Care Cancer, vol.26, pp.2039-2086, 2018.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations